The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s migraine drug Emgality (galcanezumab) for adults who suffer from recurring and episodic migraines.

The recommendation for National Health Service use was supported by data from several clinical trials in which the drug significantly reduced migraines. NICE specifically recommended the drug for adults who have “four or more migraines a month” or those who have tried three failed preventative treatment regimes.

Administered as a monthly injection, Emgality binds to and inhibits the calcitonin gene-related peptide (CGRP), a protein linked to the onset of migraines.